- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | WntResearch's new CEO comments on his first month in the position | 1 | Cision News | ||
| 01.03. | Resigning WntResearch CEO tells "It will be exciting to follow!" | 1 | Cision News | ||
| 13.02. | Spotlight Stock Market: Market Notice 32/24 Information regarding WNTResearch AB's subscription option TO 7 and TO 8 | 1 | Cision News | ||
| 12.02. | WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5 | 1 | Cision News | ||
| 09.02. | Spotlight Stock Market: Market Notice 29/24 - Last day of trading in WntResearch AB's BTU | - | Cision News | ||
| 08.02. | WntResearch announces the last day for trading in BTU and the first day for trading in warrants series TO 7 and warrants series TO 8 | - | Cision News | ||
| 07.02. | WntResearch carries out a directed issue of units to underwriters in connection with the completed rights issue | 1 | Cision News | ||
| 31.01. | WntResearch publishes outcome in rights issue | 1 | Cision News | ||
| 09.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.01.2024 | 299 | Xetra Newsboard | Das Instrument S9W CA8204391079 SHAWCOR LTD NEW EQUITY wird cum Kapitalmassnahme gehandelt am 09.01.2024 und ex Kapitalmassnahme am 10.01.2024 The instrument S9W CA8204391079 SHAWCOR LTD NEW EQUITY... ► Artikel lesen | |
| 08.01. | WntResearch publishes prospectus in connection with rights issue | 1 | Cision News | ||
| 04.01. | Spotlight Stock Market: Market Notice 2/24 - Information regarding the rights issue from WntResearch AB | 1 | Cision News | ||
| 22.12.23 | Bulletin from the extraordinary general meeting in Wntresearch AB on 22 December 2023 | 1 | Cision News | ||
| 06.12.23 | WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5 | 1 | Cision News | ||
| 23.11.23 | WntResearch's scientific founder publishes study on WNT5A signaling in scientific journal | 1 | Cision News | ||
| 21.11.23 | WntResearch's CEO: "In a better position than ever" | 1 | Cision News | ||
| 21.11.23 | WntResearch carries out a rights issue of units of approximately SEK 56 million | 1 | Cision News | ||
| 14.07.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 14.07.2023 | 1.684 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.07.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.07.2023
Aktien
1 SE0010102095 Bibbinstruments AB
2... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| JANUX THERAPEUTICS | 56,08 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SPRINGWORKS THERAPEUTICS | 46,450 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| IMMUNOVANT | 27,490 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
| CABALETTA BIO | 10,480 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,380 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| NUVALENT | 67,95 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| ARCELLX | 51,11 | 0,00 % | Should You Be Bullish on Arcellx (ACLX)? | ||
| CULLINAN THERAPEUTICS | 27,120 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| BEAM THERAPEUTICS | 22,050 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
| EVOTEC | 9,830 | +2,13 % | ÜBERNAHME-FIEBER bei Biotech-Aktien! Evotec, Bayer, Vidac Pharma - wer folgt auf Morphosys? | Im Biotech-Sektor herrscht Übernahme-Fieber. Zuletzt hat Genmab den Kauf von ProfoundBio, das US-Biotech-Unternehmen entwickelt Medikamente gegen Eierstock- und Gebärmutterschleimhautkrebs, für 1,8... ► Artikel lesen | |
| ARVINAS | 31,900 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 34,660 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen | |
| MORPHOSYS | 66,60 | +1,45 % | Morphosys: Übernahme in Gefahr? STAT-Artikel sorgt für Verunsicherung | Am Montag nach US-Börsenschluss hat die Biotech-Gesellschaft Morphosys die Zahlen für das abgelaufene erste Quartal vorgelegt. Das Hauptaugenmerk der Anleger lag allerdings nicht auf den Ergebnissen... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,460 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |
Das Unternehmen WNTRESEARCH AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,008 Euro und damit -4,76 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
